China Announces Development Of H7N9 Vaccine

[sharon sanders]

Saturday, October 26, 2013

China Announces Development Of H7N9 Vaccine

# 7905

The Chinese press is filled this morning with reports on the development of an H7N9 vaccine, although details on clinical trials are noticeably absent.

Chinese researchers develop H7N9 flu vaccine

English.news.cn 2013-10-26 21:00:46
HANGZHOU, Oct. 26 (Xinhua) -- Chinese researchers announced Saturday they had successfully developed the vaccine for the H7N9 bird flu virus, after the flu strain had left more than 130 people infected, with 45 fatalities reported.
Shu Yuelong, director of the Chinese National Influenza Center, said this is the first influenza vaccine ever developed by Chinese scientists.
The vaccine has provided important technical support to battle the new flu strain, making contribution to the H7N9 flu virus epidemic control all over the world, said Shu, also director of the WHO Collaborating Center for Reference and Research on Influenza.
The vaccine was jointly developed by the First Affiliated Hospital under the School of Medicine of the Zhejiang University, Hong Kong University, Chinese Center for Disease Control and Prevention, National Institute for Food and Drug Control, and the Chinese Academy of Medical Sciences.
China reported the world's first human case for H7N9 bird flu infection in March. As of Friday, a total of 136 people were confirmed to have been infected with the virus, according to the National Health and Family Planning Commission. Of the infected, 45 died, representing a fatality rate of 33.1 percent.
​

Issues such as the correct amount of antigen per shot, the timing or need for a booster shot, the incidence and severity of side effects, and even the need for an adjuvant are usually sorted out during several rounds of clinical (human) testing, something that can take months or longer.

Based on this report, it isn?t entirely clear to me exactly what the status of these trials is.
​

I do note, that in another report (see China successfully developed the first vaccine strain H7N9 avian influenza virus), specific mention is made on the successful completion of ferret testing. .

Recently, the virus vaccine seed strains ferrets have passed safety evaluation experiments and test all the relevant technical requirements. The vaccine strains of the technical indicators are in line with the requirements of strains of influenza virus vaccine, available giving the H7N9 avian influenza virus infection vaccine manufacturers, to declare.
​

Animal testing is standard procedure before human clinical trials. So, your guess is as good as mine as to when this vaccine might be available in any quantity for use in the event of an outbreak.

Posted by Michael Coston at <a class="timestamp-link" href="http://afludiary.blogspot.com/2013/10/china-announces-development-of-h7n9.html" rel="bookmark" title="permanent link"><abbr class="published" itemprop="datePublished" title="2013-10-26T09:44:00-04:00">9:44 AM</abbr>

 

[Giuseppe]

Re: China Announces Development Of H7N9 Vaccine

[Source: Ifeng, full page: (LINK). Automatic translation from Chinese.]


H7N9, China: A candidate vaccine seed strain obtained through reverse genetics ready for tests

At 2:31 on October 27, 2013 Source: New Express


According to Xinhua News Agency, a consortium of Chinese scientists from the research group 26 in Hangzhou, announced that it has successfully developed a human infection with H7N9 avian influenza virus vaccine strains. It is also China's first self-developed influenza virus vaccine strains.

Zhejiang University, Hong Kong and large collaborative research completed

Currently, the vaccine seed virus strains has passed Chinese Academy of Medical Sciences Institute of Laboratory Animal Research Center for Drug Safety Evaluation ferrets safety evaluation experiments. Refer to "Chinese Pharmacopoeia" influenza virus vaccine seed strains relevant technical requirements, Chinese Academy of Food and Drug Testing is also a test of the seed strains.

Test results showed that the virus vaccine strains has a decreased pathogenicity than the wild-type H7N9 strains , the cardinality indicators are in line with the requirements of the vaccine strain of influenza virus. This means that the virus strain can be supplied to vaccine manufacturers in safety conditions.

Infectious diseases as a major national scientific and technological content of major projects, one of the results from the First Affiliated Hospital, Zhejiang University School of Medicine University of Hong Kong jointly, Chinese Center for Disease Control and other units more collaborative research is completed. Project led by the Chinese Academy of Engineering Li Lanjuan introduction, the joint Task Force on April 3 received H7N9 cases throat swab samples, and successfully isolated H7N9 avian influenza virus.

Then through reverse genetics technology to PR8 virus plasmid backbone, with its own isolated virus strains gene rearrangement, and successfully developed the H7N9 influenza vaccine seed strains.

Confirmed by sequencing the genetic variation is not stable
To ensure the safety of the vaccine seed strains, researchers will seed strains in specific pathogen-free chick embryo continuously passaged 15 generations, were confirmed by sequencing the genetic stability, did not mutate.

Influenza is a respiratory disease of global importance. World Health Organization estimates that worldwide there are 250,000 -50 million people each year due to influenza deaths, 3.0 million -500 million people become ill patients. Even in developed countries, the annual influenza mortality of up to 0.01.

In March this year, China's first reported in the world discovered a new bird flu virus - H7N9 avian influenza virus. The virus can be transmitted to humans poultry, causing severe pneumonia and life-threatening. As of October 24, China's total reported 136 cases of H7N9 avian influenza virus infection, of which 45 were fatal, fatality rate of 33.1%. The research also found that, H7N9 virus has crossed the species likely to achieve effective communication between people.

"H7N9 avian influenza virus vaccine strain successfully developed for us to win this protracted added weight." Liu Dengfeng National Health and Family Planning Commission deputy director of Science and Education Division, said that the recent emergence of new cases there. He judged, as the weather turns cold, H7N9 avian influenza may be making a comeback.

Significance

Need to change our influenza vaccine strains provided by foreign history. According to reports, because they do not have the flu vaccine strains developed technology, in the past, China needed to produce vaccines against the influenza strains need to be provided by the World Health Organization. World Health Organization Influenza Collaborating Centre for Reference and Research Director of the National Influenza Center director Shu Yuelong said that the results for the first time breaking and changing needs of our country influenza vaccine strains provided by foreign history, timely response to new influenza epidemic provide a strong technical support and for the global control of H7N9 avian influenza outbreak contributed.

The Chinese Academy of Engineering, the virus experts Hou also said that China's H7N9 strain of avian influenza virus vaccine R & D success, "not only marks the Chinese already have independently developed influenza vaccines technical reserves, but also have the time for the World Health Organization to provide qualified the ability of influenza vaccine strains for the global control of influenza contributed. "


-
-------

 

[Pathfinder]

Re: China Announces Development Of H7N9 Vaccine

Translation Google

You are here:
Hangzhou Network > Hangzhou News > science and health news

Zhejiang University First Hospital announced yesterday that people infected with H7N9 avian influenza virus vaccine strains developed

2013-10-27 06:25:01 Hangzhou Network

Into vaccine production in the near future

Academician Li Lanjuan: It is recommended in close contact with poultry, farms frequented by older people and other key groups vaccinated

Yesterday, the First Affiliated Hospital, Zhejiang University School of Medicine held a news conference to announce the H7N9 avian influenza virus infection in human vaccine strains developed.

Human infection with H7N9 avian influenza virus vaccine strain to a hospital by the Zhejiang University State Key Laboratory for Diagnosis and Treatment of Infectious Diseases led by Academician Li Lanjuan and as a research subject, the joint University of Hong Kong State Key Laboratory of Emerging Infectious Diseases, Chinese Center for Disease Control, Chinese food and drug test Research Institute and the Chinese Academy of Medical Sciences and other units more collaborative research study

System success.

"The successful development of human infection with the H7N9 avian influenza virus vaccine strain, is also China's first successful development of influenza virus vaccine, not only means that we have to deal with human infection with H7N9 avian influenza virus most effective weapon, but also indicates that future outbreaks of re- Other new influenza, we ourselves have the ability to respond and effective prevention and treatment. "Li Lanjuan academician said.

Human infection with H7N9 avian influenza virus vaccine strain

Has passed the safety assessment of animal testing and quality certification

Zhejiang University a State Key Laboratory for Diagnosis and Treatment of Infectious Diseases Hospital in April 3rd, 2013 received H7N9 cases throat swab samples 1, the P3 laboratory was successfully obtained an H7N9 avian influenza virus. Research group using reverse genetics technology, the establishment of the H7N9 subtype of influenza reassortant virus vaccine seed strains. Any vaccine production must first prepare a safe vaccine seed yield strain, with the vaccine of the "seed", the vaccine can be efficient mass production.

The research and development of human infection with H7N9 avian influenza virus vaccine seed strains serial passage in eggs 15 generations, were confirmed by sequencing did not mutate, have a good genetic stability. Seed strains has passed Chinese Academy of Medical Sciences Institute of Laboratory Animal Research Center for Drug Safety Evaluation ferrets safety evaluation experiments, as well as Chinese food and drug test Institutes refer to "Chinese Pharmacopoeia" influenza virus vaccine seed strains all the relevant technical requirements verification.

Test results show that the development of human infection with H7N9 avian influenza virus vaccine strains pathogenic than the wild-type (that is, naturally infected) H7N9 strains decreased significantly, "that is inoculated with human infection with H7N9 avian influenza virus vaccine can prevention of human infection with H7N9 avian influenza, but not pathogenic. "Li Lanjuan academician said.

In the past, other subtypes of influenza vaccine strains and provided by foreign R & D, our country can not even have their own preparation flu vaccine strains, unable to timely development and application.

The research and development of human infection with H7N9 avian influenza virus vaccine strains of influenza virus vaccine can supply manufacturers produce, through a series of evaluation and validation for new drug application, mass production into the market, there is a need for public voluntary vaccination.

Source: City Express Author: Reporter correspondent Chen Xudong Wang Zhen Xia Yanyan Editor: Gao Tingting

http://hznews.hangzhou.com.cn/kejiao/content/2013-10/27/content_4942622.htm

 

[Pathfinder]

Re: China Announces Development Of H7N9 Vaccine

Translation Google

I made H7N9 vaccine strain

At 06:44 on October 27, 2013 Source: Wen Wei Po
　　
Hangzhou October 26 newspaper Ta Kung Pao (correspondent stationed in Zhejiang reporter Jiang Ping Wu Lu Chan) , Zhejiang University School of Medicine, First Affiliated Hospital of good news today from the hospital several units coordinated joint research of H7N9 avian influenza virus vaccine strain A/ZJU01 / PR8/2013 available today infected with H7N9 bird flu virus gives vaccine manufacturers. This is our first time scientists have successfully developed a human infection with H7N9 avian influenza virus vaccine strains.

Chinese Academy of Engineering, Zhejiang University School of infectious disease diagnosis and treatment of a State Key Laboratory of Professor Li Lanjuan representation, H7N9 avian influenza virus vaccine strain has passed all required tests related technologies. The successful development of the H7N9 vaccine strain before, the domestic influenza virus vaccine strains from abroad are required to provide, can not be independent preparation, timely research, timely application.

In March this year, China's first discovery of a new H7N9 avian influenza virus can cause human infections, mainly pneumonia. As of October 24, a total of 136 cases were reported, of which 45 were fatal, fatality rate of 33.1%.

Li Lanjuan introduction, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases at April 3 swab samples a received H7N9 cases were in the P3 laboratory was successfully obtained an H7N9 avian influenza virus. On this basis, the Joint Task Force using reverse genetics technology, through PR8 influenza virus plasmid rescue system to PR8 virus plasmid backbone, with its own separate H7N9 avian influenza virus strains A/Zhejiang/DTID-ZJU01/2013 (H7N9) in HA (Ref GI: 478735268) and NA (Ref GI: 478735272) gene rearrangement, the establishment of reassortant H7N9 subtype of influenza virus strains rescue system, namely H7N9 influenza virus vaccine seed strains A/ZJU01/PR8/2013. Vaccine seed strains in specific pathogen-free (SPF) chicken embryos by serial passage 15 generations, were confirmed by sequencing did not mutate, with good genetic stability.

Currently, the vaccine seed virus strains has passed Chinese Academy of Medical Sciences Institute of Laboratory Animal Research Center for Drug Safety Evaluation ferrets safety evaluation experiments, as well as Chinese food and drug test Institutes refer to "Chinese Pharmacopoeia" influenza virus vaccine seed strains relevant technical requirements All checks. An assessment and test results show, State Key Laboratory for diagnosis and treatment of infectious disease research and development of human infection with H7N9 avian influenza virus vaccine strains pathogenic than the wild-type H7N9 virus strain decreased significantly with highly attenuated strains of influenza virus PR8 approximation; the vaccine strains of the technical indicators are in line with WHO influenza virus vaccine strain requirement for people infected with H7N9 avian influenza virus vaccine manufacturers.

It is the country in the new outbreaks of infectious diseases prevention and control of hair is an important area of ​​capacity building collaborative innovation, but also indicates that China already has independently developed strains of influenza virus vaccine technology and capacity.
Into the autumn, the temperature decreased, H7N9 avian flu began a comeback.

Recently, Zhejiang and two cases of H7N9 avian influenza occurred in patients. Currently, the two patient's condition is still very critical, yet out of danger. However, virus samples extracted from the patient analysis of the virus and the first half of the current did not mutate, is still manageable, the people do not have to panic.

As regards the use of vaccines, Li Lanjuan that it was unnecessary to go blind because of panic vaccination, and need more contact with poultry vaccinated populations can be prevented.

http://news.hexun.com/2013-10-27/159104959.html

 

[Pathfinder]

Re: China Announces Development Of H7N9 Vaccine

Translation Google

Preclinical studies H7N9 vaccine development has been completed

Morning News published on 2014-01-14 07:36

According to the Ministry of Science website reported yesterday, the Ministry of Social Development and Technology Division of Health and Family Planning Commission in conjunction with the National Science and Technology Education in Beijing recently organized a human infection with H7N9 avian influenza prevention and control research technology special issue of Progress in emergency discussions.
　　
Morning News website reported yesterday, according to the Ministry of Science, Ministry of Social Development and Technology Division of Health and Family Planning Commission in conjunction with the National Science and Technology Education in Beijing recently organized a human infection with H7N9 avian influenza prevention and control research technology special issue of Progress in emergency discussions. Meeting revealed, H7N9 avian influenza virus vaccine research topics of key technologies and product development has been completed preclinical studies.
　　
Discussion session, the subjects were in terms of unit commitment research content, research, work plans were undertaken to report on issues and topics on how to strengthen the management and coordination issues were discussed in depth.
　　
In terms of pathogen confirmed that China confirmed H7N9 virus in the first time and published in top international medical journal "New England Journal of Medicine" online, "Nature" magazine published commentary on China to make rapid pathogen and confirmed H7N9 cases in the investigation contributions fully affirmed.
　　
In vaccine development, H7N9 avian influenza virus vaccine research and development of key technologies and product development issues has been basically completed preclinical studies, the vaccine currently Hualan's H7N9 influenza vaccine R & D Co. has completed all pre-clinical studies, the State Food and Drug Administration has recently been Administration accepted; human H7N9 avian influenza vaccine antigen national reference by the national drug standard substance review experts organized by the Commission, has been formally approved.
　　
In the research and development of diagnostic reagents, only 49 days to complete the development of nucleic acid detection reagents can be used for clinical diagnosis, the Shanghai Zhijiang Biotechnology Co., Ltd., Zhongshan University, Da An Gene Co., Ltd. and Shenzhen 普瑞康 biotechnology limited companies, three companies have received Food and Drug Administration of the State registration of clinical line detection; Guangzhou Wan Fu Biotechnology Co., Ltd. produces antigen detection kit has been approved the listing, you can achieve rapid clinical screening.
　　
By 2013 月底 8, H7N9-related research results have been published nine articles in top international journals, including the "science" a "natural" one, "Lancet" 4, "New England Journal of Medicine" 3 articles for the Chinese and global public health has made important contributions.
　　
The experts on the project progress and problems in a full discussion, exchange, agreed that each research group in accordance with the mission statement of basic requirements to achieve the annual performance goals. The experts request the Task Force research and development efforts, especially in epidemiological research, vaccine research and development to further increase R & D research efforts.
　　
H7N9 outbreak remarkable technological responses, not only as the epidemic prevention and control technology to provide strong support, while exploring a new mechanism for coordinated multi-sectoral response to the Ministry of Science, Ministry of Health and Family Planning Commission, Ministry of Agriculture, State Forestry Administration, to further strengthen the China's response to public health emergencies emergency prevention and control of technological capacity building.

zhttp://www.dfdaily.com/html/21/2014/1/14/1105288.shtml

 

[sharon sanders]

Re: China Announces Development Of H7N9 Vaccine

from the Ministry of Science and Technology:

machine translation


People infected with H7N9 bird flu prevention and control research technology special issue of the emergency meeting held in Beijing to discuss progress

Date: January 13, 2014 Source: Science and Technology
December 26, the Ministry of Social Development Division of Health and Family Planning Commission in conjunction with the National Science and Technology Education in Beijing organized a person infected with H7N9 bird flu emergency prevention and control technology research progress in discussions of special topics. Epidemic Disease State Forestry Administration Wildlife Monitoring Station, Ministry of Agriculture, China Animal Disease Prevention and Control Center, Chinese Biotechnology Co., Ltd., China Academy of Food and Drug Testing, Chinese Center for Disease Control and Prevention, National Influenza Center, experimental animal studies Chinese Academy of Medical Sciences Medical The, First Affiliated Hospital of Guangzhou Medical College, and other topics relevant undertaker attended the meeting, and to report progress. The meeting also invited some experts participating in Beijing.
Discussion session, the subjects were in terms of unit commitment research content, research, work plans were undertaken to report on issues and topics on how to strengthen the management and coordination issues were discussed in depth, truly sharing of resources, unity and cooperation. In terms of pathogen confirmed that China confirmed H7N9 virus in the first time and published in top international medical journal "New England Journal of Medicine" online, "Nature" magazine published commentary on China to make rapid pathogen and confirmed H7N9 cases in the investigation contributions fully affirmed. In vaccine development, H7N9 avian influenza virus vaccine research and development of key technologies and product development issues has been basically completed preclinical studies, the vaccine currently Hualan's H7N9 influenza vaccine R & D Co. has completed all pre-clinical studies, the State Food and Drug Administration has recently been Administration accepted; human H7N9 avian influenza vaccine antigen national reference by the national drug standard substance review experts organized by the Commission, has been formally approved. In the research and development of diagnostic reagents. Only 49 days to complete the development of nucleic acid detection reagents can be used for clinical diagnosis, the Shanghai Zhijiang Biotechnology Co., Ltd., Zhongshan University, Da An Gene Co., Ltd. and Shenzhen普瑞康Biotechnology Co., Ltd., three companies have been State Food and Drug Administration registration, clinical line detection; Guangzhou Wan Fu Biotechnology Co., Ltd. produces antigen detection kit has been approved the listing, you can achieve rapid clinical screening. At the end of 8, H7N9-related research results have been published nine articles in top international journals, including the "science" a "natural" one, "Lancet" 4, "New England Journal of Medicine," 3, China and the global public health has made ​​important contributions.
The experts listened carefully to the report, and the project progress and problems in a full discussion, exchange, agreed that each research group in accordance with the mission statement of basic requirements to achieve the annual performance goals. The experts request the Task Force research and development efforts, especially in epidemiological research, vaccine research and development to further increase R & D research efforts.
The people infected with H7N9 bird flu emergency prevention and control research technology special issue will be held to discuss the progress of that research group and its research team on their research objectives and research tasks more clearly, for the smooth implementation and completion of the project quality research tasks laid a good foundation.
H7N9 outbreak remarkable technological responses, not only as the epidemic prevention and control technology to provide strong support, while exploring a new mechanism for coordinated multi-sectoral response to the Ministry of Science, Ministry of Health and Family Planning Commission, Ministry of Agriculture, State Forestry Administration, to further strengthen the China's response to public health emergencies emergency prevention and control of technological capacity building.

http://www.most.gov.cn/kjbgz/201401/t20140110_111490.htm

 

[Giuseppe]

Re: China Announces Development Of H7N9 Vaccine

Currently, all vaccines' seeds have been obtained through 'reverse genomics' technique, because classical reassortants weren't successfully developed for this novel strain.

See also: Weekly epidemiological record / Relev? ?pid?miologique hebdomadaire, 3 january 2014, 89th year / 3 janvier 2014, 89e ann?e, No. 1, 2014, 89, 1?20, http://www.who.int/wer, Meeting of the Strategic Advisory Group of Experts on immunization, November 2013 ? conclusions and recommendations

at FT: http://www.flutrackers.com/forum/showthread.php?t=215064

at WHO: http://www.who.int/wer/2014/wer8901.pdf


-
-------

 

[Pathfinder]

Re: China Announces Development Of H7N9 Vaccine

Translation Google

Shanghai completed development of H7N9 vaccine clinical trials reported positive

2014-02-07 07:470
Source: Xinmin Xinmin Editor: Chen Changfeng 　　

[Xinmin Reuters reported, according to the television news, H7 influenza viruses compared to other influenza viruses, it is rather special, traditional immunization effectiveness of inactivated virus strain is not high, for Shanghai launched the H7N9 bird flu vaccine to enhance gene vaccine effectiveness and safety of the current vaccine has been developed to complete.
　　
This two-day attack H7N9 avian influenza DNA vaccine toxicity, immunogenicity evaluation report freshly baked, 30 mice after implantation of implantable H7N9 avian influenza vaccine virus, 30 days no one died, no one found pathogenic virus infection, the effectiveness of the vaccine was initially confirmed genes, currently reporting clinical trials.
　　
It is understood, H7N9 virus was isolated after the discovery, immediately started the domestic development of vaccines and gene inactivated virus vaccines, but compared to other influenza viruses, H7 influenza virus inactivated after exposure to chemical agents protein structure will be deformed, resulting in ineffective immune response, and H7N9 DNA vaccine is the major causative gene implanted into mature H7N9 vaccine vector, equivalent to deposit into the safe and then into human cells, because the protein structure of the virus is not destroyed live destruction process will effectively stimulate the body to produce an immune response.
　　
Professor, Shanghai Institute of Emerging Infectious Diseases reproduction Xu Jianqing said: "Europe's two cases of vaccine clinical trials, is the use of inactivated H7 to do clinical trials, the results of clinical evaluation of a failure, after taking into account the risk, and then develop a vaccine to go Another route is to use genetic engineering to do the vaccine. "
　　
Currently, Shanghai has started the development of H7N9 avian influenza antibodies, that is, the infected person's body produces antibodies to the virus bulk copy, if successful will help new infections treatment.

zhttp://shanghai.xinmin.cn/msrx/2014/02/07/23428878.html

 

[Pathfinder]

Re: China Announces Development Of H7N9 Vaccine

Translation Google

Experts say the H7N9 bird flu vaccine clinical evaluation needs at least 6 years

At 9:56 on February 10, 2014
Source: First Financial Daily

For the newly developed H7N9 avian influenza DNA vaccine, Professor, Shanghai Institute of Emerging Infectious Diseases Xu Jianqing reproduction yesterday told the "First Financial Daily" reporters, clinical evaluation is divided into three phases, at least six years, there are still some risks during the .

Shanghai Institute of Infectious Diseases, Shanghai Public Health Clinical Center has a new hair and reproduce the 7th news release, H7N9 avian influenza DNA vaccine has completed initial development in Shanghai, has now entered clinical trials reporting stage.

Xu Jianqing told the newspaper, the team developed a vaccine using gene technology. The specific method is to try the main immunogen gene H7N9 is implanted into a mature H7 vaccine vector, equivalent to deposit into the safe and then into human cells, the membrane protein structure of the virus will not be destroyed, can effectively stimulate body to produce protective neutralizing antibodies. 30 in vaccinated mice after infection of H7N9 avian influenza virus and then, 30 days without a disease.

However, the effectiveness and safety of vaccines should be verified by further clinical evaluation.

"Phase I clinical evaluation is mainly for vaccine safety, the second phase is the safety and immunogenicity, three are immunogenic and protective." 徐建青 said that after the completion of Phase III clinical, be possible to enter the market.

Xu Jianqing said the biggest advantage of DNA vaccine is safe, because the gene vaccine using gene universal vaccine carrier, which has been internationally proven through clinical trials to be safe. "The safety of the vaccine itself, in theory there is no problem, specific to our own vaccine, or pre-clinical and clinical going to go verify."

However, the main risk is genetic vaccine immunogenicity in humans, monkeys and other larger animals seem weak. "Can be complementary techniques to overcome this weakness on clinical, laboratory we are doing another set of fake virus technology can be used as a complementary technology to enhance the immunogenicity of DNA vaccine."

In addition, H7N9 viruses are constantly variation, "It depends on which part of the variation, we chose the site of the membrane protein, and the work done from the current data, we have a number of vaccines for 1996, 2003 and 2007 of H7 viruses have a protective effect. "Xu Jianqing said.

For R & D H7N9 avian influenza virus vaccine, a number of companies and organizations inside and outside there are many breakthroughs. For example in Taiwan Guoguang Biotechnology Co., Ltd. developed the H7N9 bird flu vaccine is expected to enter clinical trials in March; Last May, the U.S. Greffex and Protein Science has also announced the adoption of modified adenovirus vectors through research H7N9 virus vaccine candidates; addition American Novavax, Canada, Medicago, Sinopharm Group, China Biotechnology Co., Ltd., a subsidiary of Beijing Sinovac Sinovac Biotech Ltd., Hualan companies, and China Taiwan's Guoguang Biotechnology Co., Ltd. also have declared vaccine development stage, none of these companies are currently entering clinical phase.

zhttp://fashion.ifeng.com/health/yiyao/chanjing/detail_2014_02/10/33653020_0.shtml

 

[Pathfinder]

Re: China Announces Development Of H7N9 Vaccine

Translation Google

H7N9 vaccine has not been talked about by vaccination is still too early clinical studies

February 11, 2014 08:15:24 Source: Beijing Youth Daily

According to the National Planning Commission yesterday for the Guardian in January 2014 national notifiable infectious diseases Bulletin, January total of 127 cases of human infection with the H7N9 bird flu cases, including 31 cases of death. And as of February 9, the number of infections has risen to 185 cases and 34 deaths. H7N9 vaccine for the recent public concern, the National Health and Family Planning Commission, said spokesman Yao Hongwen, joint prevention and control mechanism associated units will further advance the transformation of vaccine development and achievements, and to make a vaccine for approval in accordance with the development of the epidemic, Listed preparation.
　　
Several units reporting development of a vaccine clinical trials
　　
Recently, the Shanghai Public Health Clinical Center, Shanghai Institute of Emerging Infectious Diseases reproduction to the outside world, H7N9 avian influenza antibodies developed in vitro testing is nearing completion, is expected to be finalized next month, the fastest antibody screening, has entered clinical trials. The news immediately aroused wide public concern. In this regard, Chinese Center for Disease Control and Prevention, control of viral diseases, deputy director, director of the National Influenza Center, said Shu Yuelong, in fact in addition to Shanghai, the country currently has a number of units developed vaccine has been declared a national clinical trial stage.
　　
In this regard, the National Health and Family Planning Commission spokesman Yao Hongwen said yesterday, in 2013, Zhejiang University successfully isolated an H7N9 avian influenza virus, based on the use of reverse genetics technology, has successfully developed a H7N9 bird flu vaccine seed strains. Vaccine seed strain of the virus has now refer to "Chinese Pharmacopoeia" influenza virus vaccine seed strains required by the relevant technical safety evaluation experiments ferrets Chinese Medical Science Research Institute of Laboratory Animal Drug Safety Evaluation Center, and the Chinese Academy of Food and Drug Testing All test.
　　
So, when the vaccine can really reach clinical use stage? Earlier, experts said, according to the standard development process, after completion of clinical studies to be about 6 years. In this regard, Shu Yuelong said that at present the country has not completed a clinical research enterprise.

On human vaccination is valid and so after not known, it is necessary to wait until the success of clinical research to verify the safety and effectiveness of vaccines in order to determine how vaccination against the light of developments and trends of the epidemic. Yaohong Wen also said joint prevention and control mechanism will further promote the conversion of the relevant units of vaccine development and achievements, and to make a vaccine for approval in accordance with the development of the epidemic, the listed preparations.
　　
Contact with live poultry is still the main source of infection
　　
According to local health statistics inform the health department this year, and more people infected with H7N9 provinces new confirmed cases of avian influenza 185 cases and 34 deaths. And last March to July, more than 130 cases of infection only. The reason for this human infection with H7N9 avian influenza cases increasing, Shu Yuelong said the main reason is the opportunity to the people to eat poultry during the Spring Festival more, also many opportunities for human exposure. Therefore, contact with poultry or live bird markets remained the major source of infection.
　　
"As long as there is no change in lifestyle, cases will continue to occur on." Shu Yuelong, said he also proposed that the H7N9 avian influenza virus in all large-scale farms have not detected any loophole, and found that the virus is in some small, irregular farms, so as to gradually reduce the risk of infection, the future should be gradually transformed into large-scale poultry farming, modern breeding, sale, Popular, which is chilled sales.
　　
Meanwhile, a comprehensive analysis of the recent outbreak associated with the etiology, epidemiology and clinical manifestations of monitoring information, the current form of H7N9, the Yaohong Wen said at the press conference yesterday, the experts judged that the current human infection with H7N9 avian flu epidemic characteristics No significant changes occurred sporadic, still sporadic cases mainly occurred monitoring found no virus mutation of public health, the spread of the virus from the birds to humans remains, experts predict that the recent Mainland of China may continue to occur in people infected with H7N9 bird flu cases. But now, the virus does not have the ability to spread from person to person, individual clusters of disease cases is mainly due between family, close contact between relatives cause, does not mean that the virus has the ability to have an effective person to person.
　　
News Memory
　　
The difference between H7N9 avian influenza virus with common flu virus
　　
1 source of infection is different. Seasonal flu is spread between people, is spread to others through the patient. H7N9 virus infection source was contaminated environment, that is, live bird markets.
　　
2 symptoms is not the same. Seasonal flu symptoms generally very light, most people can be cured, rarely cause severe, the proportion of deaths is very low. The high proportion of severe H7N9 fatality rate is also high.
　　
3 common to the spread of the flu once high season, such as winter and spring, can cause large-scale spread in the population, such as school, many students are able to be infected. The H7N9 remains an animal-to-human sporadic cases, which is highly distributed. (Text / reporter Liu Yang)

zhttp://big5.xinhuanet.com/gate/big5/news.xinhuanet.com/health/2014-02/11/c_119273154.htm